

## FIȘA DE VERIFICARE

a îndeplinirii standardelor minimale în vederea obținerii atestatului de abilitare  
în cadrul I.O.S.U.D. Universitatea de Medicină și Farmacie “Carol Davila” București

Domeniile de doctorat: Medicină, Farmacie

### I. Date despre candidat

Nume: GUJA

Prenume: CRISTIAN

#### 1. Doctor în științe

DA       NU

Titlul tezei de doctorat: *Epidemiologia genetică a diabetului zaharat de tip 1 în România*

Ordinul de confirmare: 5663 din 15 XII 2003

#### 2. Medic/ medic dentist/farmacist primar în specialitatea postului (la disciplinele cu corespondent în rețeaua Ministerului Sănătății)

DA       NU

Ordinul de confirmare: VIII.d/69746/21.01.2009

### II. Date numerice privind îndeplinirea standardelor minimale naționale, conform anexelor nr. 20 și 23 ale Ordinului Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016

#### 1. Articole publicate în reviste cotate ISI în calitate de autor principal

Criteriaul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de autor principal	10	16

**Criteriu îndeplinit:**

DA       NU

**Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact**

**AP1.** Ionescu-Tîrgoviște C, **Guja C**, Călin A, Moța M. An increasing trend in the incidence of type 1 diabetes in children aged 0 – 14 years in Romania. Ten years (1988 – 1997) EURODIAB study experience. *J Ped Endocrinol Metab* 2004, 17(7): 983-991. IMPACT FACTOR 0.903

**AP2.** **Guja C**, Guja L, Nutland S, Rance H, Sebastien M, Todd JA, Ionescu-Tirgoviste C. Type 1 diabetes genetic susceptibility encoded by HLA DQB1 genes in Romania. *J Cell Mol Med* 2004, 8(2): 249-256. IMPACT FACTOR 2.153

**AP3.** Ioacara S, Ionescu-Tirgoviste C, **Guja C**. Life expectancy in adult diabetes patients treated with insulin from diagnosis. *Acta Endocrinologica (Buc)* 2012, 8(1): 153-162. IMPACT FACTOR 0.450

**AP4.** Culman M, Serafinceanu C\*, Mihai A, **Guja C**. Sleep apnea syndrome in diabetic patients. *Rom J Legal Med* 2013, 21(1): 47-50. IMPACT FACTOR 0.152

**AP5.** Culman M, **Guja C\***, Mihai A, Serafinceanu C. Depression screening and risk profile in diabetic patients. *Rom J Legal Med* 2013, 21(3): 197-200. IMPACT FACTOR 0.152

**AP6.** Ionescu-Tirgoviste C, Gagniuc PA, **Guja C**. A challenge for the autoimmune diabetogenic mechanism in type 1 diabetes? *Acta Endocrinologica (Buc)* 2014, 10(3): 317-328. IMPACT FACTOR 0.268

**AP7.** Ioacara S, **Guja C\***, Reghina A, Martin S, Sirbu A, Fica S. Cardiovascular mortality in type 2 diabetes patients with incident exposure to insulin glargine. *J Diabetes Res* 2015, 2015: 962346. IMPACT FACTOR 2.431

**AP8.** Ionescu-Tîrgoviște C, Gagniuc PA, **Guja C**. Structural properties of gene promoters highlight more than two phenotypes of diabetes. *PLoS One* 2015, 10(9): e0137950. IMPACT FACTOR 3.057

**AP9.** Lixandru D, Moraru L, Alexandru P, Stoian I, Roșca A, Ghiță M, Căruntu C, Căruntu A, Ionescu-Tîrgoviște C, **Guja C**. Implications of antioxidant enzyme paraoxonase 2 in insulin synthesis and secretion. *Rev Chim (Bucharest)* 2016, 67(11): 2332-2336. IMPACT FACTOR 1.232

**AP10.** Doroș R, Lixandru D, Moraru L, Petcu L, Tudosoiu J, Mitu M, Picu A, Ionescu-Tîrgoviște C, **Guja C**. Resting metabolic rate in type 2 diabetes – accuracy of predictive equations. *Rom Biotechnol Lett* 2016, 21(6): 12033-12038. IMPACT FACTOR 0.396

**AP11.** Ștefan DS, Mihai A, Bajko D, Lixandru D, Petcu L, Picu A, Smeu B, Copăescu C, Ionescu-Tîrgoviște C, **Guja C.** Comparison of sleeve gastrectomy and conservatory treatment effect on biochemical and hormonal profile of obese type 2 diabetes subjects: CREDOR randomized controlled study results. *Rev Chim (Bucharest)* 2017, 68(7): 1622-1627. IMPACT FACTOR 1.412

**AP12.** Ioacă S, **Guja C\***, Georgescu O, Martin S, Sîrbu A, Purcaru M, Fica S. Patients treated with insulin and sulphonylurea are at increased mortality risk as compared with those treated with insulin plus metformin. *Acta Endocrinologica (Buc)* 2017, 13(3): 329-333. IMPACT FACTOR 0.411

**AP13.** Ioacă S, **Guja C\***, Reghină A, Martin S, Sîrbu A, Fica S. All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes. *Endocrine Research* 2018, 43(2): 97-105. IMPACT FACTOR 1.518

**AP14.** Frías JP, Hardy E, Ahmed A, Öhman P, Jabbour S, Wang H, **Guja C.** (2018) Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. *Diabetes Obes Metab* 2018, 20(6): 1520-1525. IMPACT FACTOR 5.980

**AP15.** **Guja C,** Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. *Diabetes Obes Metab* 2018, 20(7): 1602-1614. IMPACT FACTOR 5.980

**AP16.** Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, **Guja C.** Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. *Diabetes Care* 2018, Aug 6. pii: dc180680. doi: 10.2337/dc18-0680. (online ahead of print) IMPACT FACTOR 13.397

## 2. Articole publicate în reviste cotate ISI în calitate de coautor

<b>Criteriul</b>	<b>Standard minim</b>	<b>Realizat</b>
<b>Număr articole publicate în reviste cotate ISI în calitate de coautor</b>	<b>5</b>	<b>33</b>

**Criteriu îndeplinit:**

**DA**       **NU**

**Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact**

**CA1.** Herr M, Dudbridge F, Zavattari P, Cucca F, **Guja C**, March R, Campbell RD, Barnett AH, Bain SC, Todd JA, Koeleman BP. Evaluation of fine mapping strategies for a multifactorial disease locus: systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. *Hum Mol Genet* 2000, 9(9): 1291-301. IMPACT FACTOR 9.048

**CA2.** Ionescu-Tîrgoviște C, **Guja C**, Herr M, Cucca F, Welsh K, Bunce M, Marshall S, Todd JA. Low frequency of HLA DRB1\*03 - DQB1\*02 and DQB1\*0302 haplotypes in Romania is consistent with the country's low incidence of type 1 diabetes. *Diabetologia* 2001, 44 [Suppl 3]: B60-B66. IMPACT FACTOR 6.299

**CA3.** Dahlman I, Eaves IA, Kosoy R, Morrison VA, Heward J, Gough SC, Allahabadia A, Franklyn JA, Tuomilehto J, Tuomilehto-Wolf E, Cucca F, **Guja C**, Ionescu-Tirgoviste C, Stevens H, Carr P, Nutland S, McKinney P, Shield JP, Wang W, Cordell HJ, Walker N, Todd JA, Concannon P. (2002) Parameters for reliable results in genetic association studies in common disease. *Nat Genet* 2002, 30(2): 149-150. IMPACT FACTOR 26.711

**CA4.** Maier LM, Twells RCJ, Howson JMM, Lam AC, Clayton DG, Smyth DJ, Savage D, Carson D, Patterson CC, Smink LJ, Walker NM, Burren OS, Nutland S, Rance H, Tuomilehto-Wolf E, Tuomilehto J, **Guja C**, Ionescu-Tîrgoviște C, Undlien DE, Rønningen KS, Cucca F, Todd JA. Testing the possible negative association of type 1 diabetes and atopic disease by analysis of the interleukin 4 receptor gene. *Genes Immun* 2003, 4(7): 469-475. IMPACT FACTOR 3.637

**CA5.** Ueda H, Howson JMM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KMD, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RCJ, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, **Guja C**, Ionescu-Tîrgoviște C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SCL. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* 2003, 423(6939): 506-511. IMPACT FACTOR 30.979

**CA6.** Nejentsev S, **Guja C**, McCormack R, Cooper J, Howson JMM, Nutland S, Rance H, Walker N, Undlien D, Rønningen KS, Tuomilehto-Wolf E, Tuomilehto J, Ionescu-Tîrgoviște C, Gale EAM, Bingley PJ, Gillespie KM, Savage DA, Carson DJ, Patterson CC, Maxwell AP, Todd JA. Association of intercellular adhesion molecule-1 gene with type 1 diabetes. *Lancet* 2003, 362(9397): 1723-1724. IMPACT FACTOR 18.316

**CA7.** Eftychi C, Howson JMM, Barratt B, Vella A, Payne F, Smyth DJ, Twells RCJ, Walker NM, Rance H, Tuomilehto-Wolf E, Tuomilehto J, Undlien DE, Rønningen KS, **Guja C**,

Ionescu-Tîrgoviște C, Savage D, Todd JA. Analysis of the type 2 diabetes - associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. *Diabetes* 2004, 53(3): 870-873. IMPACT FACTOR 8.848

**CA8.** Vella A, Howson JMM, Barratt B, Twells RCJ, Rance H, Nutland S, Tuomilehto-Wolf E, Tuomilehto J, Undlien DE, Rønningen KS, **Guja C**, Ionescu-Tîrgoviște C, Savage D, Todd JA. Lack of association of the Ala<sup>45</sup>Thr polymorphism and other common variants of the NeuroD gene with type 1 diabetes. *Diabetes* 2004, 53(4): 1158-1161. IMPACT FACTOR 8.848

**CA9.** Lowe CE, Cooper JD, Chapman JM, Barratt BJ, Twells RCJ, Green EA, Savage DA, **Guja C**, Ionescu-Tîrgoviște C, Tuomilehto-Wolf E, Tuomilehto J, Todd JA, Clayton DG. Cost-effective analysis of candidate genes using htSNPs: a staged approach. *Genes Immun* 2004, 5(4): 301–305. IMPACT FACTOR 3.718

**CA10.** Barratt BJ, Payne F, Lowe CE, Hermann R, Healy BC, Harold D, Concannon P, Gharani N, McCarthy MI, Olavesen MG, McCormack R, **Guja C**, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Gillespie KM, Tuomilehto-Wolf E, Tuomilehto J, Bennett ST, Clayton DG, Cordell HJ, Todd JA. Remapping the Insulin Gene/IDDM2 locus in Type 1 diabetes. *Diabetes* 2004, 53(7): 1884-1889. IMPACT FACTOR 8.848

**CA11.** Nejentsev S, Godfrey L, Snook H, Rance H, Nutland S, Walker NM, Lam AC, **Guja C**, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Tuomilehto-Wolf E, Tuomilehto J, Newport MJ, Clayton DG, Todd JA. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. *Hum Mol Genet* 2004, 13(15): 1633-1639. IMPACT FACTOR 7.801

**CA12.** Hulme JS, Barratt BJ, Twells RCJ, Cooper JD, Lowe CE, Howson JMM, Lam AC, Smink L, Savage DA, Undlien DE, **Guja C**, Ionescu-Tîrgoviște C, Tuomilehto-Wolf E, Tuomilehto J, Todd JA. Association analysis of the lymphocyte-specific protein tyrosine kinase (LKC) gene in type 1 diabetes. *Diabetes* 2004, 53(9): 2479-2482. IMPACT FACTOR 8.848

**CA13.** Nejentsev S, Cooper JD, Godfrey L, Howson JM, Rance H, Nutland S, Walker NM, **Guja C**, Ionescu-Tirgoviste C, Savage DA, Undlien DE, Ronningen KS, Tuomilehto-Wolf E, Tuomilehto J, Gillespie KM, Ring SM, Strachan DP, Widmer B, Dunger D, Todd JA. Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. *Diabetes* 2004, 53(10): 2709-2712. IMPACT FACTOR 8.848

**CA14.** Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JM, Vella A, Nutland S, Rance HE, Maier L, Barratt BJ, **Guja C**, Ionescu-Tirgoviste C, Savage DA, Dunger DB, Widmer B, Strachan DP, Ring SM, Walker N, Clayton DG, Twells RC, Gough SC, Todd JA. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. *Diabetes* 2004, 53(11): 3020-3023. IMPACT FACTOR 8.848

**CA15.** Maier LM, Smyth DJ, Vella A, Payne F, Cooper JD, Pask R, Lowe C, Hulme J, Smink LJ, Fraser H, Moule C, Hunter KM, Chamberlain G, Walker N, Nutland S, Undlien DE, Ronningen KS, **Guja C**, Ionescu-Tirgoviste C, Savage DA, Strachan DP, Peterson LB, Todd JA, Wicker LS, Twells RC. Construction and analysis of tag single nucleotide polymorphism maps for six human-mouse orthologous candidate genes in type 1 diabetes. *BMC Genet* 2005, 6:9. IMPACT FACTOR 1.769

**CA16.** Smyth DJ, Howson JM, Lowe CE, Walker NM, Lam AC, Nutland S, Hutchings J, Tuomilehto-Wolf E, Tuomilehto J, **Guja C**, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Savage D, Dunger DB, Twells RC, McArdle WL, Strachan DP, Todd JA. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. *Nat Genet* 2005, 37(2): 110-111. IMPACT FACTOR 25.797

**CA17.** Payne F, Smyth DJ, Pask R, Cooper JD, Masters J, Wang WY, Godfrey LM, Bowden G, Szeszko J, Smink LJ, Lam AC, Burren O, Walker NM, Nutland S, Rance H, Undlien DE, Ronningen KS, **Guja C**, Ionescu-Tirgoviste C, Todd JA, Twells RC. No evidence for association of the TATA-box binding protein glutamine repeat sequence or the flanking chromosome 6q27 region with type 1 diabetes. *Biochem Biophys Res Commun* 2005, 331(2): 435-441. IMPACT FACTOR 3.000

**CA18.** Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, **Guja C**, Ionescu-Tirgoviste C, Widmer B, Dunger DB, Savage DA, Walker NM, Clayton DG, Todd JA.) A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. *Nat Genet* 2006, 38(6): 617-619. IMPACT FACTOR 24.176

**CA19.** Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, Lowe CE, Szeszko JS, Hafler JP, Zeitels L, Yang JHM, Vella A, Nutland S, Stevens HE, Schuilenburg H, Coleman G, Maisuria M, Meadows W, Smink LJ, Healy B, Burren OS, Lam AAC, Ovington NR, Allen J, Adlem E, Leung H-T, Wallace C, Howson JMM, **Guja C**, Ionescu-Tirgoviste C, Genetics of Type 1 Diabetes in Finland, Simmonds MJ, Heward JM, Gough SCL, Dunger DB, the Wellcome Trust Case Control Consortium, Wicker LS & Clayton DG. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet* 2007, 39(7): 857-864. IMPACT FACTOR 25.556

**CA20.** Heltianu C, Manea S-A, **Guja C**, Mihai C, Ionescu-Tirgoviste C. Correlation of low molecular weight advanced glycation end products and nitric oxide metabolites with chronic complications in type 1 diabetic patients. *Cent Eur J Biol* 2008, 3(3): 243-249. IMPACT FACTOR 0.662

**CA21.** Ioacă S, Lichiardopol R, Ionescu-Tirgoviste C, Cheța D, Sabău S, **Guja C**, Farcașiu E, Tiu C. Improvements in life expectancy in type 1 diabetes patients in the last six decades. *Diabetes Res Clin Pract* 2009, 86(2):146-151. IMPACT FACTOR 2.160

- CA22.** Heltianu C, Manea S-A, **Guja C**, Robciuc A, Ionescu-Tîrgoviște C. Polymorphism in exon 7 of the endothelial nitric oxide synthase gene is associated with low incidence of microvascular damage in type 1 diabetic neuropathy. *Cent Eur J Biol* 2009, 4(4): 521-527. IMPACT FACTOR 0.915
- CA23.** Manea SA, Robciuc A, **Guja C**, Heltianu C. Identification of gene variants in NOS3, ET-1 and RAS that confer risk and protection against microangiopathy in type 2 diabetic obese subjects. *Biochem Biophys Res Commun* 2011, 407(3): 486-490. IMPACT FACTOR 2.484
- CA24.** Ioacără S, **Guja C**, Ionescu-Tîrgoviște C, Fica S, Sabău S, Radu S, Micu A, Tiu C. Improvements in life expectancy in adult type 2 diabetes patients in the last six decades. *Diabetes Res Clin Pract* 2011, 92(3): 400-404. IMPACT FACTOR 2.754
- CA25.** Ioacara S, **Guja C**, Fica S, Ionescu-Tirgoviste C. The dynamics of life expectancy over the last six decades in elderly people with diabetes. *Diabetes Res Clin Pract* 2013, 99(2): 217-222. IMPACT FACTOR 2.536
- CA26.** Ioacara S, **Guja C**, Ionescu-Tirgoviste C, Fica S, Roden M. Cancer specific mortality in insulin-treated type 2 diabetes patients. *PLoS One*, 2014, 9(3): e93132. IMPACT FACTOR 3.234
- CA27.** Moța E, Popa SG, Moța M, Mitrea A, Penescu M, Tuță L, Serafinceanu C, Hâncu N, Gârneață L, Verzan C, Lichiardopol R, Zetu C, Căpușă C, Vlăduțiu D, **Guja C**, Catrinoiu D, Bala C, Roman G, Radulian G, Timar R, Mihai B. Prevalence of chronic kidney disease and its association with cardio-metabolic risk factors in the adult Romanian population: the PREDATORR study. *Int Urol Nephrol* 2015, 47(11): 1831-1838. IMPACT FACTOR 1.292
- CA28.** Mota M, Popa SG, Mota E, Mitrea A, Catrinoiu D, Cheta DM, **Guja C**, Hancu N, Ionescu-Tirgoviste C, Lichiardopol R, Mihai BM, Popa AR, Zetu C, Bala CG, Roman G, Serafinceanu C, Serban V, Timar R, Veresiu IA, Vlad AR. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. *J Diabetes*, 2016, 8(3): 336-344. IMPACT FACTOR 3.039
- CA29.** Popa S, Moța M, Popa A, Moța E, Serafinceanu C, **Guja C**, Catrinoiu D, Hâncu N, Lichiardopol R, Bala C, Popa A, Roman G, Radulian G, Timar R, Mihai B. Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study. *J Endocrinol Invest* 2016, 39(9): 1045-1053. IMPACT FACTOR 2.633
- CA30.** Frías JP, **Guja C**, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes Endocrinol* 2016, 4(12): 1004-1016. IMPACT FACTOR 19.742

**CA31.** Popa SG, Moța M, Mihălțan FD, Popa A, Munteanu I, Moța E, Serafinceanu C, **Guja C**, Hâncu N, Catrinoiu D, Lichiardopol R, Bala C, Mihai B, Radulian G, Roman G, Timar R. Associations of smoking with cardiometabolic profile and renal function in a Romanian population-based sample from the PREDATORR cross-sectional study. *Eur J Gen Pract* 2017, 23(1): 164-170. IMPACT FACTOR 1.410

**CA32.** Roșu MM, Popa SG, Moța E, Popa A, Manolache M, **Guja C**, Bala C, Moța M. Cardiovascular risk assessment in the adult (aged 40-79 years) Romanian population. *Acta Endocrinologica (Buc)* 2018, 14(2): 227-234. IMPACT FACTOR 0.411

**CA33.** Jabbour SA, Frías JP, **Guja C**, Hardy E, Ahmed A, Öhman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. *Diabetes Obes Metab* 2018, 20(6): 1515-1519. IMPACT FACTOR 5.980

**3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)**

<b>Criteriul</b>	<b>Standard minim</b>	<b>Realizat</b>
<b>(ISI) Factor cumulat de impact autor principal</b>	<b>10</b>	<b>39.892</b>

**Criteriu îndeplinit:**

**DA**       **NU**

**4. Indexul Hirsch**

<b>Criteriul</b>	<b>Standard minim</b>	<b>Realizat</b>
<b>Index Hirsch</b>	<b>6</b>	<b>18</b>

**Criteriu îndeplinit:**


**DA**       **NU**

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică

**Data**

25.09.2018

**Semnătura candidatului**



**Note asupra metodei de calcul:**

1. O revistă cotate ISI este o revistă pentru care Thomson Reuters calculează și publică factorul de impact în „Journal Citation Reports”;
2. Autorul sau autorii principali ai unei publicații se consideră a fi oricare dintre următorii:
  - a. Primul autor
  - b. Autorul corespondent
  - c. Alți autori, a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuția primului autor sau a autorului corespondent
  - d. Ultimul autor
3. În analiză vor fi incluse articole originale și reviews. În cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații in extenso (nu rezumate).
4. Articolele din cadrul standardelor minimale și obligatorii trebuie să fie publicate, nu în curs de publicare (nu se acceptă adevărințe).
5. Factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCIAP). FCIAP = suma factorilor de impact ai articolelor publicate de autor în calitate de autor principal în reviste cotate ISI;
6. Va fi luat în considerare Indexul Hirsch calculat utilizând ISI Web of Science, Core Collection, Thomson Reuters, pentru întreaga carieră a candidatului („all years”);